Page last updated: 2024-11-09

xe 991, anthracenone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone: neurotransmitter release enhancer and potassium channel blocker; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID656732
CHEMBL ID342375
CHEBI ID35046
SCHEMBL ID2761225
MeSH IDM0290455

Synonyms (23)

Synonym
BRD-K42748308-300-01-2
gtpl2596
tocris-2000
NCGC00025339-01 ,
xe991
LS-190926 ,
chebi:35046 ,
CHEMBL342375 ,
xe-991
10,10-bis(4-pyridinylmethyl)-9(10h)-anthracenone
10,10-bis(pyridin-4-ylmethyl)anthracen-9-one
122955-42-4
KHJFBUUFMUBONL-UHFFFAOYSA-N
SCHEMBL2761225
xe 991
10,10-bis(pyridin-4-ylmethyl)anthracen-9(10h)-one
xe-991, >=98% (hplc)
dr 960418
Q27089244
9(10h)-anthracenone, 10,10-bis(4-pyridinylmethyl)-
bdbm50529215
HY-108577A
CS-0084011

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Oral or intraperitoneal administration of QO58-lysine, which has improved bioavailability and a half-life of approximately 3 h in plasma, can reverse inflammatory pain in rodent animal models."( Activation of neuronal Kv7/KCNQ/M-channels by the opener QO58-lysine and its anti-nociceptive effects on inflammatory pain in rodents.
Li, G; Ma, TY; Qi, JL; Song, Y; Teng, BC; Wang, K; Zhang, F; Zhang, HL, 2016
)
0.43

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves were obtained with increasing concentrations of the KCNQ((2-5)) selective positive modulator, retigabine or with the KCNQ((1-5)) negative modulator XE991."( Functional effects of the KCNQ modulators retigabine and XE991 in the rat urinary bladder.
Rode, F; Rønn, LC; Sheykhzade, M; Svalø, J, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
anthracenesCompounds containing an anthracene skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (24)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
15-lipoxygenase, partialHomo sapiens (human)Potency1.99530.012610.691788.5700AID887
thyroid stimulating hormone receptorHomo sapiens (human)Potency3.16230.001318.074339.8107AID926; AID938
cytochrome P450 2C9 precursorHomo sapiens (human)Potency19.95260.00636.904339.8107AID883
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency0.50120.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency12.58930.020010.786931.6228AID912
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency19.95260.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency0.50121.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Potassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)IC50 (µMol)0.05500.04800.05150.0550AID1611064
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)32.00000.00091.901410.0000AID1611065
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (25)

Processvia Protein(s)Taxonomy
chemical synaptic transmissionPotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
nervous system developmentPotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
action potentialPotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
calmodulin bindingPotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
ankyrin bindingPotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
plasma membranePotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
node of RanvierPotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
axon initial segmentPotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
synapsePotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
membranePotassium voltage-gated channel subfamily KQT member 2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1611075Inhibition of D3 receptor (unknown origin)2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders.
AID1611080Inhibition of CYP3A4 (unknown origin) at 10 uM using DBOMF as substrate measured for each min for 6 mins by fluorescence based assay relative to control2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders.
AID1611072Inhibition of alpha1A adrenergic receptor (unknown origin)2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders.
AID1611064Inhibition of Kv7.2 in human HEK293 cells incubated for 1 hr by thallium flux assay2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders.
AID1611074Inhibition of PBR receptor (unknown origin)2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders.
AID182145Compound was tested in vivo for microdialysis ACh release after peroral administration of 10 mg/kg water at the duration of 100 minutes1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
2-Fluoro-4-pyridinylmethyl analogues of linopirdine as orally active acetylcholine release-enhancing agents with good efficacy and duration of action.
AID175343Compound was tested in vitro for its ability to enhance the K+-stimulated release of [3H]acetylcholine from rat hippocampal slices preloaded with [3H]choline at 10 uM1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
2-Fluoro-4-pyridinylmethyl analogues of linopirdine as orally active acetylcholine release-enhancing agents with good efficacy and duration of action.
AID1611066Inhibition of CYP3A4 (unknown origin) at 50 uM using DBOMF as substrate measured for each min for 6 mins by fluorescence based assay relative to control2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders.
AID1611068Stability in 1:1 MeCN:0.2N aq. HCl assessed as percent remaining at 0.3 mM and 60 degC incubated for 24 hrs by LC/MS analysis2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders.
AID175499Compound was tested in vitro for its ability to enhance the K+-stimulated release of [3H]acetylcholine from rat hippocampal slices preloaded with [3H]-Choline.1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
2-Fluoro-4-pyridinylmethyl analogues of linopirdine as orally active acetylcholine release-enhancing agents with good efficacy and duration of action.
AID1611065Inhibition of ERG in human HEK293 cells incubated for 1 hr by thallium flux assay2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders.
AID1611063Inhibition of Kv7.2/7.3 in human tsA201 cells assessed as effect on channel currents at -60 mV holding potential at 1.5 uM by whole cell patch clamp assay relative to control2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders.
AID1611069Kinetic solubility in 2.5 % DMSO/water at 3.2 uM to 100 uM incubated for 18 hrs by spectrometry2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders.
AID1611073Inhibition of alpha1 adrenergic receptor (unknown origin)2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders.
AID1611071Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 18 hrs by celltiter-glo assay2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders.
AID1874647Anticonvulsant activity in PTZ induced C57BL/6 mouse acute seizure model assessed as time for maximal seizure at 3 mg/kg, ip pretreated for 30 mins followed by PTZ injection and measured upto 30 mins by Liittjohann's scale analysis
AID1611070Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 18 hrs by celltiter-glo assay2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders.
AID1874646Anticonvulsant activity in PTZ induced C57BL/6 mouse acute seizure model assessed as seizure score at 3 mg/kg, ip pretreated for 30 mins followed by PTZ injection and measured upto 30 mins by Liittjohann's scale analysis
AID182150Compound was tested in vivo for microdialysis ACh release after peroral administration of 5 mg/kg suspended in water1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
2-Fluoro-4-pyridinylmethyl analogues of linopirdine as orally active acetylcholine release-enhancing agents with good efficacy and duration of action.
AID1611067Metabolic stability in human liver microsomes assessed as percent remaining at 1 mM incubated for 1 hr by LC/MS analysis2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders.
AID1346723Human Kv7.1 (Voltage-gated potassium channels)2000Molecular pharmacology, Jun, Volume: 57, Issue:6
Molecular basis for differential sensitivity of KCNQ and I(Ks) channels to the cognitive enhancer XE991.
AID1346696Human Kv7.2 (Voltage-gated potassium channels)1998Science (New York, N.Y.), Dec-04, Volume: 282, Issue:5395
KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel.
AID1346699Human Kv7.4 (Voltage-gated potassium channels)2001American journal of physiology. Cell physiology, Apr, Volume: 280, Issue:4
KCNQ4 channels expressed in mammalian cells: functional characteristics and pharmacology.
AID1346689Human Kv7.5 (Voltage-gated potassium channels)2000The Journal of biological chemistry, Aug-04, Volume: 275, Issue:31
KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (149)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (2.01)18.2507
2000's57 (38.26)29.6817
2010's79 (53.02)24.3611
2020's10 (6.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.35 (24.57)
Research Supply Index5.02 (2.92)
Research Growth Index5.37 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other150 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]